New drug combo shows promise for young women with brittle bones
NCT ID NCT04800367
First seen Feb 28, 2026 · Last updated May 12, 2026 · Updated 5 times
Summary
This study tests whether a year of romosozumab followed by a year of denosumab can safely increase bone density in 30 premenopausal women aged 18-48 with idiopathic osteoporosis. Participants receive monthly injections of romosozumab for 12 months, then denosumab every 6 months for another year. The goal is to improve bone mass and reduce fracture risk, with results compared to a prior group treated with teriparatide.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREMENOPAUSAL IDIOPATHIC OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.